Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder
β Scribed by Abraham Pavlotsky; Abraham Eidelman; Frida Barak; Haim Alon; Dr. Yoav Horn
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 301 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2-week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicityrelated symptoms. Cystoscopic follow-up showed a gradual decline in the presence of tumor to a complete response rate of 87.1 % at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.
π SIMILAR VOLUMES
A rare case of coexisting sarcoma and carcinoma of the urinary bladder is reported and the literature is reviewed. Because of the differences in the histogenesis and prognosis, such cases should be differentiated from cases of carcinosarcoma of the urinary bladder.
## Abstract Ureteral obstruction is a frequent complication of transitional cell carcinoma (TCC), known as a poor prognostic sign and indicative of advanced disease. We investigated retrospectively the medical records of 122 consecutive patients who suffered from invasive TCC of the urinary bladder
Sixty patients with superficial papillary bladder cancer, Stages Ta and T1, received chemoprophylactic treatment to prevent recurrences after the complete resection of the primary lesion. The prophylactic regimen consisted of endovesical instillations alternating doxorubicin and mitomycin C. The fir